US Supply Chain Partners Get Details On Designing Information Security Systems
Executive Summary
In draft guidance on evolving drug product tracking program, the US FDA gives thumbs-up on distributed or semi-distributed architecture for data security; support for aggregation and inference; a one-minute bar for verification.
You may also be interested in...
US FDA: Pharmaceutical Distribution Entering DSCSA Compliance ‘Stabilization Period’
Agency officials advise drug supply chain partners what stabilization activities they expect to see during one-year “enforcement discretion” period; industry lawyers advise that anyone found coasting could face discretionary enforcement. More discretion, more guidance in the works, including a final ruling on state preemption.
Lack Of Readiness In Responding To DSCSA Verification Requests Major Concern
Roughly half of all pharmaceutical manufacturers have misgivings they will have the necessary systems to electronically verify saleable returns under DSCSA, even though they must respond to these requests within 24 hours.
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.